Rhinocort Turbuhaler

Rhinocort Turbuhaler may be available in the countries listed below.

Ingredient matches for Rhinocort Turbuhaler

Budesonide

Budesonide is reported as an ingredient of Rhinocort Turbuhaler in the following countries:

• Iceland


• Ireland


• Norway


• Sweden


• Switzerland

International Drug Name Search

Beyaz

Beyaz is a brand name of drospirenone/ethinyl estradiol/levomefolate calcium, approved by the FDA in the following formulation(s):

BEYAZ (drospirenone; ethinyl estradiol; levomefolate calcium - tablet; oral)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: September 24, 2010
  
  Strength(s): 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG ^[RLD]

Has a generic version of Beyaz been approved?

No. There is currently no therapeutically equivalent version of Beyaz available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Beyaz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol
  Patent 5,798,338
  Issued: August 25, 1998
  Inventor(s): Backensfeld; Thomas & Tack; Johannes
  Assignee(s): Schering Aktiengesellschaft
  A method and pharmaceutical compositions are disclosed for reducing oxidative degradation of 17 .alpha.-ethinylestradiol comprising combining the estradiol with an effective amount of cyclodextrin, thus forming a cyclodextrin clathrate of the steroid.
  
  Patent expiration dates:
  
  
  • July 10, 2015
    
    ✓ 
    Drug product
  
  



• 
  Stable crystalline salts of 5-methyltetrahydrofolic acid
  Patent 6,441,168
  Issued: August 27, 2002
  Inventor(s): Rudolf; Müller & Rudolf; Moser & Thomas; Egger
  Assignee(s): Eprova AG
  This invention relates to stable crystalline salts of 5-methyl-(6R,S)-, -(6S)- and -(6R)-tetrahydrofolic acid, to methods of producing these salts and to the use thereof use as a constituent for the production of drugs or as a food additive, and to preparations containing these salts.
  
  Patent expiration dates:
  
  
  • April 17, 2020
    
    ✓ 
    Drug substance
  
  



• 
  Cyclodextrin-drospirenone inclusion complexes
  Patent 6,958,326
  Issued: October 25, 2005
  Inventor(s): Backensfeld; Thomas & Heil; Wolfgang & Lipp; Ralph
  Assignee(s): Schering AG
  Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
  
  Patent expiration dates:
  
  
  • December 30, 2021
    
    ✓ 
    Drug product
  
  



• 
  Compositions of estrogen-cyclodextrin complexes
  Patent 7,163,931
  Issued: January 16, 2007
  Inventor(s): Backensfeld; Thomas & Heil; Wolfgang & Lipp; Ralph
  Assignee(s): Schering Aktiengesellchaft
  Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
  
  Patent expiration dates:
  
  
  • March 3, 2022
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  



• 
  Composition for contraception
  Patent RE37564
  Issued: February 26, 2002
  Inventor(s): Jürgen; Spona & Bernd; Düsterberg & Frank; Lüdicke
  Assignee(s): Schering Aktiengesellschaft
  A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
  
  Patent expiration dates:
  
  
  • June 30, 2014
    
    ✓ 
    Drug product
  
  



• 
  Composition for contraception
  Patent RE37838
  Issued: September 10, 2002
  Inventor(s): Jürgen; Spona & Bernd; Düsterberg & Frank; Lüdicke
  Assignee(s): Schering Aktiengesellschaft
  A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
  
  Patent expiration dates:
  
  
  • June 30, 2014
    
    ✓ 
    Drug product
  
  



• 
  Composition for contraception
  Patent RE38253
  Issued: September 16, 2003
  Inventor(s): Jürgen; Spona & Bernd; Düsterberg & Frank; Lüdicke
  Assignee(s): Schering Aktiengesellschaft
  A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
  
  Patent expiration dates:
  
  
  • June 30, 2014
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 24, 2013 - NEW COMBINATION
  
  
  • September 24, 2013 - NEW PRODUCT
  
  

See also...

• Beyaz Consumer Information (Drugs.com)
• Beyaz Consumer Information (Wolters Kluwer)
• Beyaz Consumer Information (Cerner Multum)
• Beyaz Advanced Consumer Information (Micromedex)
• Drospirenone/Ethinyl Estradiol/Levomefolate Consumer Information (Wolters Kluwer)
• Drospirenone, ethinyl estradiol, and levomefolate Consumer Information (Cerner Multum)
• Drospirenone, ethinyl estradiol, and levomefolate Advanced Consumer Information (Micromedex)

Pravastatin Helvepharm

Pravastatin Helvepharm may be available in the countries listed below.

Ingredient matches for Pravastatin Helvepharm

Pravastatin

Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Pravastatin Helvepharm in the following countries:

• Switzerland

International Drug Name Search

Enangel

Enangel may be available in the countries listed below.

Ingredient matches for Enangel

Dexketoprofen

Dexketoprofen tromethamine (a derivative of Dexketoprofen) is reported as an ingredient of Enangel in the following countries:

• Spain

International Drug Name Search

Mitomycin-C

Mitomycin-C may be available in the countries listed below.

Ingredient matches for Mitomycin-C

Mitomycin

Mitomycin is reported as an ingredient of Mitomycin-C in the following countries:

• Greece


• India


• Israel


• Italy


• New Zealand


• Peru


• Poland


• Spain


• Taiwan

International Drug Name Search

Lorophyn

Lorophyn may be available in the countries listed below.

Ingredient matches for Lorophyn

Nonoxinol

Nonoxinol 9 (a derivative of Nonoxinol) is reported as an ingredient of Lorophyn in the following countries:

• Argentina


• Peru

International Drug Name Search

Eficef

Eficef may be available in the countries listed below.

Ingredient matches for Eficef

Cefixime

Cefixime is reported as an ingredient of Eficef in the following countries:

• Romania

International Drug Name Search

F-Exina

F-Exina may be available in the countries listed below.

Ingredient matches for F-Exina

Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of F-Exina in the following countries:

• Mexico

International Drug Name Search

Nibid

Nibid may be available in the countries listed below.

Ingredient matches for Nibid

Nimesulide

Nimesulide is reported as an ingredient of Nibid in the following countries:

• Bangladesh

International Drug Name Search

Micotrim

Micotrim may be available in the countries listed below.

Ingredient matches for Micotrim

Clotrimazole

Clotrimazole is reported as an ingredient of Micotrim in the following countries:

• Argentina

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Micotrim in the following countries:

• Argentina

International Drug Name Search

Permanganate de Potassium Lafran

Permanganate de Potassium Lafran may be available in the countries listed below.

Ingredient matches for Permanganate de Potassium Lafran

Potassium Permanganate

Potassium Permanganate is reported as an ingredient of Permanganate de Potassium Lafran in the following countries:

• France

International Drug Name Search

Carboplatino Microsules

Carboplatino Microsules may be available in the countries listed below.

Ingredient matches for Carboplatino Microsules

Carboplatin

Carboplatin is reported as an ingredient of Carboplatino Microsules in the following countries:

• Argentina

International Drug Name Search